{"id":"typhim-vi-sanofi-pasteur-msd","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site pain or erythema"},{"rate":"5-15","effect":"Headache"},{"rate":"5-15","effect":"Myalgia"},{"rate":"1-5","effect":"Fever"},{"rate":"5-10","effect":"Malaise"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains purified Vi polysaccharide capsular antigen from Salmonella typhi, which is conjugated to tetanus toxoid to enhance immunogenicity. Upon administration, it triggers both humoral and cellular immune responses, leading to the production of protective antibodies against typhoid fever. This provides active immunization against infection with Salmonella typhi.","oneSentence":"Typhim Vi is an inactivated typhoid vaccine that stimulates the immune system to produce antibodies against Salmonella typhi polysaccharide antigen.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:36:21.674Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Active immunization against typhoid fever caused by Salmonella typhi"}]},"trialDetails":[{"nctId":"NCT02429531","phase":"PHASE4","title":"Polysaccharide Antibody Response Study","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2015-10","conditions":"Specific Polysaccharide Antibody Deficiency","enrollment":200},{"nctId":"NCT02286544","phase":"PHASE1","title":"Effects of Oxygen Treatment on Mechanisms Involved in Ischemia-reperfusion Injury: A Pilot Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2014-10","conditions":"Myocardial Infarction, Inflammation, Acute Coronary Syndrome (ACS)","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Typhim Vi (Sanofi Pasteur MSD)","genericName":"Typhim Vi (Sanofi Pasteur MSD)","companyName":"Universitaire Ziekenhuizen KU Leuven","companyId":"universitaire-ziekenhuizen-ku-leuven","modality":"Biologic","firstApprovalDate":"","aiSummary":"Typhim Vi is a vaccine against Salmonella typhi, developed by Sanofi Pasteur MSD. It is a small molecule vaccine used to prevent typhoid fever, and has been studied in clinical trials for various conditions including Specific Polysaccharide Antibody Deficiency and Acute Coronary Syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}